Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review
Open Access
- 12 February 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2203
Abstract
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and Sézary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing positive outcomes. Notably, the drug has demonstrated significant response rates, disease stability, and extended periods of progression-free survival, suggesting its applicability in cases with multiple treatment lines. Its safety profile is generally manageable, with adverse events (AEs) primarily related to the skin, infusion-related reactions, drug eruptions, autoimmune diseases, and skin disorders. The latter seem to appear as CCR4 can promote the skin-specific homing of lymphocytes, and MOG is directed against this receptor. While combination with immunostimulatory agents like interferon alpha and interleukin 12 has shown promising results, caution is urged when combining with PD1 inhibitors due to the heightened risk of immune-mediated AEs. The introduction of MOG as a systemic treatment implies a significant advancement in managing these diseases, supported by its favorable safety profile and complementary mechanisms.Keywords
Funding Information
- Kyowa Kirin
This publication has 112 references indexed in Scilit:
- Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary SyndromeJAMA Dermatology, 2021
- Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current TherapyCurrent Treatment Options in Oncology, 2021
- Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphomaThe Journal of Pathology: Clinical Research, 2020
- Treatment with mogamulizumab or lenalidomide for relapsed adult T‐cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experienceHematological Oncology, 2020
- Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T‐Cell Lymphoma or Adult T‐Cell LymphomaThe Journal of Clinical Pharmacology, 2019
- Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical ResponseJAMA Dermatology, 2019
- Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary SyndromeJAMA Dermatology, 2018
- Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumabAnnals of Hematology, 2016
- Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell LymphomasCurrent Hematologic Malignancy Reports, 2012
- The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T‐cell lymphoma patientsAmerican Journal of Hematology, 2012